Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 2:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Paratek Pharmaceuticals Inc Clear all
Completed Phase 3 Interventional Results available

Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

NCT02877927
View directory record Official record
Conditions
Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions
Omadacycline, Linezolid
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 5, 2026, 2:25 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Omadacycline in Cystic Fibrosis

NCT04460586
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Omadacycline Injection [Nuzyra], Omadacycline Oral Tablet [Nuzyra]
Drug
Lead sponsor
Paul Beringer
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 5, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

NCT03716024
View directory record Official record
Conditions
Infectious Skin Disease, Bacterial Skin Disease
Interventions
PTK 0796, Linezolid
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
11
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 5, 2026, 2:25 AM EDT
Terminated Phase 3 Interventional Results available

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

NCT00865280
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
PTK 0796, linezolid, moxifloxacin
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Fountain Valley, California • La Mesa, California • Oceanside, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 5, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Results available

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

NCT02531438
View directory record Official record
Conditions
Bacterial Pneumonia, Community-Acquired Infections
Interventions
Omadacycline, Moxifloxacin
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Mobile, Alabama • Laguna Hills, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 5, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

NCT05217537
View directory record Official record
Conditions
Bacterial Infections
Interventions
Omadacycline Injection [Nuzyra], Omadacycline Oral Tablet
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
8 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Little Rock, Arkansas • Long Beach, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 5, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis

NCT03425396
View directory record Official record
Conditions
Uncomplicated Urinary Tract Infection, Cystitis
Interventions
Omadacycline tablets, Nitrofurantoin capsules
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
23
States / cities
Chula Vista, California • La Mesa, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 5, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Results available

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

NCT02378480
View directory record Official record
Conditions
Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions
Omadacycline, Linezolid
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
18
States / cities
Mobile, Alabama • Chula Vista, California • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 5, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Omadacycline Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

NCT04144374
View directory record Official record
Conditions
Diabetes, Wound Infection, Healthy Volunteers
Interventions
Omadacycline, Microdialysis Catheter Insertion
Drug · Procedure
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 5, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia

NCT04160260
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Omadacycline
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • Clearwater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 5, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Microbiome Effect of Omadacycline on Healthy Volunteers

NCT06030219
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Omadacycline, Vancomycin Pill, Moxifloxacin
Drug
Lead sponsor
University of Houston
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 5, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

NCT04922554
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
Interventions
Omadacycline Oral Tablet, Placebo
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Stanford, California • Washington D.C., District of Columbia • Clearwater, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 5, 2026, 2:25 AM EDT
Completed Phase 3 Interventional

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

NCT03747458
View directory record Official record
Conditions
Bilateral Nasal Polyposis
Interventions
OPN-375
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • Bakersfield, California • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 5, 2026, 2:25 AM EDT
Active, not recruiting Phase 2 Interventional

Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection

NCT05753215
View directory record Official record
Conditions
Bone Infection, Joint Infection, Bone and Joint Infection
Interventions
Omadacycline Pill, Standard of Care
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 5, 2026, 2:25 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

NCT06850805
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
OPN-375, Placebo
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 5, 2026, 2:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Intravenous (IV) Omadacycline on Gut Microbiome

NCT05515562
View directory record Official record
Conditions
Microbial Colonization
Interventions
Omadacycline Injection
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 40 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 5, 2026, 2:25 AM EDT
Not yet recruiting Phase 2 Interventional

Omadacycline for Treatment Refractory Mycoplasma Genitalium Urethritis

NCT07853742
View directory record Official record
Conditions
Mycoplasma Genitalium Infection, Urethritis
Interventions
Omadacycline Oral Tablet
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 5, 2026, 2:25 AM EDT